Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.72
-0.0600-3.37%
Post-market: 1.730.0099+0.58%19:55 EST
Volume:1.91M
Turnover:3.33M
Market Cap:142.72M
PE:-0.60
High:1.83
Open:1.77
Low:1.67
Close:1.78
Loading ...

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel Mrna-Lnp Gene Editing Therapeutics

THOMSON REUTERS
·
22 Oct 2024

Editas Medicine Inc - to Combine CRISPR Cas12a With Genevant's Lnp Technology

THOMSON REUTERS
·
22 Oct 2024

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

GlobeNewswire
·
22 Oct 2024

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

GlobeNewswire
·
19 Oct 2024

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Simply Wall St.
·
12 Oct 2024

Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)

TIPRANKS
·
07 Oct 2024

National Bank on DRI Healthcare's Casgevy Stream Acquisition

MT Newswires
·
05 Oct 2024

DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million

MT Newswires
·
04 Oct 2024

Editas Medicine Secures $57M Deal for Gene-Editing Technology

TIPRANKS
·
04 Oct 2024

Editas Medicine Sells Future License Fees for Gene-Editing Technology for $57 Million

MT Newswires Live
·
04 Oct 2024

Editas Medicine Announces $50+ Million Monetization Financing With Dri Healthcare Trust

THOMSON REUTERS
·
04 Oct 2024

Press Release: Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Dow Jones
·
04 Oct 2024

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Simply Wall St.
·
26 Sep 2024

Editas Medicine Price Target Maintained With a $8.00/Share by RBC Capital

Dow Jones
·
19 Sep 2024

Editas Medicine (EDIT) Receives a Hold from RBC Capital

TIPRANKS
·
19 Sep 2024

JonesTrading Initiates Editas Medicine at Buy With $13 Price Target

MT Newswires Live
·
18 Sep 2024